IGM Biosciences announced a strategic pivot and pipeline transformation. The company’s lead candidates include imvotamab, a CD20 x CD3 bispecific T cell engager being developed in rheumatoid arthritis, systemic lupus erythematosus and myositis, and IGM-2644, a CD38 x CD3 bispecific T cell engager, which is expected to enter into a clinical study for generalized myasthenia gravis by the end of 2024. IGM also announced today that Mary Beth Harler has been appointed as CEO and to the board of directors. Harler joined IGM in 2021 as president, autoimmunity and inflammation.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IGMS:
- Biotech Alert: Searches spiking for these stocks today
- IGM Biosciences price target lowered to $11 from $12 at H.C. Wainwright
- IGM Biosciences price target lowered to $24 from $25 at Truist
- IGM Biosciences price target raised to $25 from $20 at Wedbush
- IGM Biosciences price target raised to $12 from $11 at JPMorgan